Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Viewpoint, Markus Schürks and Hans-Christoph Diener make the case that patent foramen ovale closure should not be used as a treatment for migraine. They argue that the causal link between patent foramen ovale and migraine has not been verified and highlight shortcomings in the existing data.
Several studies have indicated that a relationship exists between patent foramen ovale (PFO) and the incidence of migraine; however, the nature of the relationship and whether PFO closure could be used as a treatment for migraine are controversial. In this Viewpoint, Gian Paolo Anzola lists evidence in support of a relationship between PFO and migraine and suggests that, subject to further trials, PFO closure could in the future benefit some patients with migraine.
Creange et al. describe the case of a woman who presented with sudden-onset neuropathy, elevated levels of vascular endothelial growth factor, thrombocytosis, leukocytosis, and thrombosis. Diagnosed with POEMS syndrome, the patient was successfully treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation.